Clinical Trial Update: Compassionate Single Subject Use of FG-3019 (FibroGen) in Locally Advanced, Unresectable Pancreatic Cancer [NA]

View source ↗

Summary

Compassionate single-subject use of pamrevlumab (FG-3019) for locally advanced, unresectable pancreatic cancer has been withdrawn from the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Pamrevlumab (pamrevlumab)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Pancreatic Cancer | NA | Status: WITHDRAWN